Atrial Flutter
1 original drugsAtrial Flutter has 1 FDA-approved novel treatment, led by AOP HLTH US across 10 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Atrial Flutter Market Leaders
Companies with the most FDA-approved novel Atrial Flutter drugs.
Atrial Flutter Clinical Pipeline by Phase
8 industry-sponsored trials across 7 sponsors
Novel Atrial Flutter Drugs by Company (New molecular entities)
1 company has an FDA-approved novel drug for Atrial Flutter.
Reformulations (10 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Atrial Flutter Drug Targets
Molecular targets of approved and investigational Atrial Flutter drugs — 10 targets tracked.
Generic Drugs (7 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs